Literature DB >> 10229204

p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma.

A Fujimoto1, R Morita, N Hatta, K Takehara, M Takata.   

Abstract

In an attempt to examine whether the inactivation of p16INK4a is an important early event in the development of sporadic melanoma in vivo, we have systematically analysed 46 uncultured primary cutaneous melanomas. Loss of heterozygosity (LOH) of chromosome region 9p21-22 (where the p16INK4a resides) was detected in 11 tumours (24%) by PCR-based LOH analyses. Direct sequencing of all three exons of the p16INK4a gene in these 11 tumours revealed no somatic mutation although germline mutations which have not been reported previously as common polymorphisms were detected in two patients. Further sequencing analyses of the p16INK4a gene exon 2 in 19 additional tumours with no evidence of LOH on 9p21-22 identified only one heterozygous C- >T mutation at codon 81 altering a proline to a leucine. A sensitive methylation-specific PCR assay did not reveal de novo methylation of the 5'CpG island in exon 1 of the p16INK4a gene in any of the tumours showing 9p21-22 allelic loss or a heterozygous p16INK4a mutation. Complete loss of p16INK4a protein, most likely due to homozygous deletion of the p16INK4a gene, was observed in 6 (15%) out of 39 evaluable cases by immunohistochemical analyses on frozen sections using two different anti-p16INK4a antibodies. The results show that inactivation of p16INK4a is not as frequent in primary melanoma as has been reported in cell lines, and warrant further search for another tumour suppressor on 9p21-22. This study also emphasizes the importance of examining uncultured primary tumours rather than cell lines to define early events in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229204     DOI: 10.1038/sj.onc.1202803

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

Review 1.  Melanoma genetics and the development of rational therapeutics.

Authors:  Yakov Chudnovsky; Paul A Khavari; Amy E Adams
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

2.  Id1 regulation of cellular senescence through transcriptional repression of p16/Ink4a.

Authors:  R M Alani; A Z Young; C B Shifflett
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

3.  Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase.

Authors:  Oddbjørn Straume; Johanna Smeds; Rajiv Kumar; Kari Hemminki; Lars Andreas Akslen
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

4.  Immunostaining for the tumour suppressor gene p16 product is a useful marker to differentiate melanoma metastasis from lymph-node nevus.

Authors:  Daniela Mihic-Probst; Parvin Saremaslani; Paul Komminoth; Philipp U Heitz
Journal:  Virchows Arch       Date:  2003-10-24       Impact factor: 4.064

5.  Rapid repair of UVA-induced oxidized purines and persistence of UVB-induced dipyrimidine lesions determine the mutagenicity of sunlight in mouse cells.

Authors:  Ahmad Besaratinia; Sang-In Kim; Gerd P Pfeifer
Journal:  FASEB J       Date:  2008-03-07       Impact factor: 5.191

Review 6.  Early cancers of the skin: clinical, histopathological, and molecular characteristics.

Authors:  Minoru Takata; Toshiaki Saida
Journal:  Int J Clin Oncol       Date:  2005-12       Impact factor: 3.850

7.  Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma.

Authors:  Caroline Conway; Samantha Beswick; Faye Elliott; Yu-Mei Chang; Juliette Randerson-Moor; Mark Harland; Paul Affleck; Jerry Marsden; D Scott Sanders; Andy Boon; Margaret A Knowles; D Timothy Bishop; Julia A Newton-Bishop
Journal:  Genes Chromosomes Cancer       Date:  2010-05       Impact factor: 5.006

8.  Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. The Melanoma Cooperative Group.

Authors:  G Palmieri; A Cossu; P A Ascierto; G Botti; M Strazzullo; A Lissia; M Colombino; M Casula; C Floris; F Tanda; M Pirastu; G Castello
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

Review 9.  Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities.

Authors:  Goran Micevic; Nicholas Theodosakis; Marcus Bosenberg
Journal:  Clin Epigenetics       Date:  2017-04-04       Impact factor: 6.551

Review 10.  Issues affecting molecular staging in the management of patients with melanoma.

Authors:  G Palmieri; M Casula; M C Sini; P A Ascierto; A Cossu
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.